GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » DaVita Inc (STU:TRL) » Definitions » Equivalent Admissions #

DaVita (STU:TRL) Equivalent Admissions # : 0.00 (As of . 20)


View and export this data going back to 1995. Start your Free Trial

What is DaVita Equivalent Admissions #?

Equivalent Admissions # are a general measure used to indicate combined inpatient and outpatient volumes.

The historical rank and industry rank for DaVita's Equivalent Admissions # or its related term are showing as below:

STU:TRL's Equivalent Admissions # is not ranked *
in the Healthcare Providers & Services industry.
Industry Median:
* Ranked among companies with meaningful Equivalent Admissions # only.

DaVita Equivalent Admissions # Historical Data

The historical data trend for DaVita's Equivalent Admissions # can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

DaVita Equivalent Admissions # Chart


DaVita (STU:TRL) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » DaVita Inc (STU:TRL) » Definitions » Equivalent Admissions #
Comparable Companies
UHS THC CHE EHC ACHC ENSG OPCH PACS SEM SGRY HCA SAU:4013 SZSE:300015 XTER:FRE BKK:BDMS ADX:PUREHEALTH XTER:FME XKLS:5225 HKSE:06618 BSP:RDOR3
Traded in Other Exchanges
DVA:USA TRL:Germany DVAI34:Brazil
Address
2000 16th Street, Denver, CO, USA, 80202
Website
https://www.davita.com
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,000 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives about two thirds of U.S. sales at government (primarily Medicare) reimbursement rates, with the remainder coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.

DaVita (STU:TRL) Headlines

No Headlines